KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Prelimi...(ow-dose estrogen product. The Company...),Health

The Company believes Evamist(TM) could attain peak annual sales of approximately $125 million with gross margins consistent with those currently being achieved by Ther-Rx Corporation. The Company expects Evamist(TM) to significantly augment the women's health offerings of Ther-Rx Corporation.

ETHEX Corporation

-- 65.2% net revenue growth year to date

-- Gross profit improving 89.2% through nine months of fiscal 2008,

resulting in gross profit margin of 65.9%

-- 76.4% market share of new prescriptions for the 100 mg strength and

62.7% market share of new prescriptions for the 200 mg strength of

Metoprolol Succinate Extended Release Tablets as of the end of December

2007

-- Net revenues for the 100 mg and 200 mg strengths of Metoprolol

Succinate Extended Release Tablets contributed $36.4 million during

third quarter of fiscal 2008 resulting in revenues for the six months

since launch of $86.8 million

-- Net revenues for all six strengths of Diltiazem HCl Extended-Release

Capsules (generic alternative to Tiazac(R), Forest Laboratories)

contributed $6.4 million during the third quarter of fiscal 2008, up

5.0% compared to $6.1 million reported for the third quarter of fiscal

2007

Net revenues for the Company's specialty generic/non-branded business increased 57.8%, to $102.2 million for the third quarter of fiscal 2008, compared to $64.7 million for the third quarter of fiscal 2007. For the nine- month period, ETHEX reported net revenues of $281.0 million, or a 65.2% improvement over revenues of $170.1 million in the prior year period. Gross margins for the third quarter of fiscal 2008 reached 66.5%, up from 58.9% in the prior year quarter and were 65.9% year to date, compared to 57.5% last year.

Both revenue and margin growth during the quarter and nine-month period were favorably i
'/>"/>